Reviva pharmaceuticals announces intent to file an ind for brilaroxazine in psoriasis after promising preclinical data

Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model

RVPH Ratings Summary

RVPH Quant Ranking